Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
The DOI matches its Crossref record; 37 of the 51 references it cites were found in a registry or an index.
Abstract
CONTEXT: The gastrointestinal peptide hormone, peptide YY(3-36) (PYY(3-36)), is implicated to be a postprandial satiety factor. OBJECTIVE: The aim of this study is to assess the safety, tolerability, and efficacy of intranasal PYY(3-36) to induce weight loss in obese patients. DESIGN: The study was designed as a randomized, 2-wk, single-blind placebo run-in followed by a 12-wk double-blind, placebo-controlled treatment period. SETTING: The study was set within a private and institutional practice. PATIENTS: A total of 133 obese patients (body mass index, 30-43 kg/m(2); age, 18-65 yr) participated in the study. INTERVENTION: Placebo or 200- or 600-microg PYY(3-36) was administered as an intranasal spray 20 min before breakfast, lunch, and dinner in conjunction with a hypocaloric diet and exercise. MAIN OUTCOME MEASURE: Body weight was the main outcome measure. RESULTS: The number of patients completing 12 wk on the drug was 38 of 43 (88%), 31 of 44 (70%), and 12 of 46 (26%) for placebo, 200 microg three times a day (t.i.d.) and 600 microg t.i.d., respectively. In the 600 microg t.i.d. group, 27 of 46 (59%) patients discontinued due to nausea and vomiting. Among all randomized patients who took at least one drug dose and had a postbaseline measurement, the mean body weight change from baseline was -2.8, -3.7, and -1.4 kg for placebo, 200 and 600 microg, respectively. The least squares mean difference (95% confidence interval) between placebo and 200 microg was -0.9 (-2.6, 0.7) kg (P = 0.251). A difference of 2.11 kg was sought. No meaningful inference can be drawn from the few patients who completed the study on 600 microg. CONCLUSIONS: Intranasal PYY(3-36) as administered at these intervention doses and preprandial timing is not efficacious in inducing weight loss in obese patients after 12 wk of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [94]
In the citing paper
“Some PYY agents evaluated for monotherapy of obesity resulted in unacceptable nausea and vomiting and limited weight reduction [165,168].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [168]
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Human distribution and release of a putative new gut hormone, peptide YY
Adrian, T. E., Ferri, G.-L., Bacarese-Hamilton, A. J., Fuessl, H. S., Polak, J. M., & Bloom, S. R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90211-2 · Cited by 1,065
Roux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907
Tatemoto, K., & Mutt, V. (1980) · Nature · doi:10.1038/285417a0 · Cited by 659
Attenuated Peptide YY Release in Obese Subjects Is Associated with Reduced Satiety
le Roux, C. W., Batterham, R. L., Aylwin, S. J. B., Patterson, M., Borg, C. M., Wynne, K. J., Kent, A., Vincent, R. P., Gardiner, J., Ghatei, M. A., et al. (2006) · Endocrinology · doi:10.1210/en.2005-0972 · Cited by 552
The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats
Koda, S., Date, Y., Murakami, N., Shimbara, T., Hanada, T., Toshinai, K., Niijima, A., Furuya, M., Inomata, N., Osuye, K., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1266 · Cited by 431
Korner, J., Bessler, M., Cirilo, L. J., Conwell, I. M., Daud, A., Restuccia, N. L., & Wardlaw, S. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1076 · Cited by 417
Research works printed but not linked: 2
- Batterham, 2003, Inhibition of food intake in obese subjects by peptide YY3–36., N Engl J Med, 349, 941
- Wyss, 1998, 76, 363
Cited by
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373
“Administration of intra-nasal PYY3-36 was tested in obese human subjects as a weight-loss treatment, but encountered significant problems with nausea and vomiting.(48) In this study, placebo or intra-nasal PYY3-36 was administered at a dose of 200 mcg 3 times daily or 600 mcg 3 times daily for 12 weeks.”
BackgroundMethodWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal ef fi cacy with poor tolerability [94].”
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Intranasal administration of 200 or 600 mg PYY(3e36) three times daily before each meal for 12 weeks in human subjects with obesity failed to exhibit either a dose-dependent or meaningful reduction in body weight [110].”
BackgroundBenedict, C., Kern, W., Schultes, B., Born, J., & Hallschmid, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2606 · Cited by 296
Bessesen, D. H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0520 · Cited by 257
“Recent data using intranasal administration have produced mixedresults (42).”
BackgroundAppetite regulation and weight control: the role of gut hormones
Perry, B., & Wang, Y. (2012) · Nutrition & Diabetes · doi:10.1038/nutd.2011.21 · Cited by 217
The role of gut hormones in the regulation of body weight and energy homeostasis
Karra, E., & Batterham, R. L. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 209
The neuropeptide Y system: Pathophysiological and therapeutic implications in obesity and cancer
Zhang, L., Bijker, M. S., & Herzog, H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.011 · Cited by 189
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Bowels control brain: gut hormones and obesity
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.93 · Cited by 172
“48 Rodent studies also provide evidence of an anorectic synergy when IAPP is coadministered with either PYY(3-36) or cholecystokinin (CCK).”
Pharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 165
NPY receptors as potential targets for anti‐obesity drug development
Yulyaningsih, E., Zhang, L., Herzog, H., & Sainsbury, A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01363.x · Cited by 138
“PYY3-36 infusion, particularly at higher doses (Degen et al., 2005; Gantz et al., 2007; Sloth et al., 2007a; le Roux et al., 2008).”
BackgroundStrategic Approach to Fit-for-Purpose Biomarkers in Drug Development
Wagner, J. A. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094611 · Cited by 137
Self-citationGastrointestinal hormones and regulation of gastric emptying
Camilleri, M. (2019) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000448 · Cited by 129
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A., Koliaki, C. C., & Mantzoros, C. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 128
The future role of gut hormones in the treatment of obesity
Troke, R. C., Tan, T. M., & Bloom, S. R. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 125
Psychopharmacological advances in eating disorders
Himmerich, H., & Treasure, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1383895 · Cited by 119
“the CB1 receptor antagonist taranabant [161], the peptide YY3-36 [162] which is a product of enteroendocrine cells, the pancreatic and lipase inhibitor cetilistat [163].”
BackgroundNeuroendocrinology of reward in anorexia nervosa and bulimia nervosa: Beyond leptin and ghrelin
Berner, L. A., Brown, T. A., Lavender, J. M., Lopez, E., Wierenga, C. E., & Kaye, W. H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.018 · Cited by 140
Agile delivery of protein therapeutics to CNS
Yi, X., Manickam, D. S., Brynskikh, A., & Kabanov, A. V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.017 · Cited by 115
Engineered commensals for targeted nose-to-brain drug delivery
Shen, H., Aggarwal, N., Cui, B., Foo, G. W., He, Y., Srivastava, S. K., Li, S., Seah, M. Z. X., Wun, K. S., Ling, H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.017 · Cited by 125
“In future studies, we plan to incorporate biocontainment strategies, such as kill switches, into the Lp strain to prevent these genetically modified microorganisms from being released into the environment.”
Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids
Alhabeeb, H., AlFaiz, A., Kutbi, E., AlShahrani, D., Alsuhail, A., AlRajhi, S., Alotaibi, N., Alotaibi, K., AlAmri, S., Alghamdi, S., et al. (2021) · Nutrients · doi:10.3390/nu13020481 · Cited by 106
Sloth, B., Davidsen, L., Holst, J. J., Flint, A., & Astrup, A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2007 · Cited by 104
“However, side effects in the form of nausea, vomiting, abdominal discomfort, fullness, and sweating have also been reported both with iv infusion (4, 16) as well as with nasal administration (8) of PYY3-36, and at present it cannot be ruled out that part of the appetite suppressant effect of PYY3-36 is due to nausea a…”
BackgroundTargeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
Lin, S., Shi, Y.-C., Yulyaningsih, E., Aljanova, A., Zhang, L., Macia, L., Nguyen, A. D., Lin, E.-J. D., During, M. J., Herzog, H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008488 · Cited by 96
“has been shown to induce nausea or conditioned taste aversion at doses that reduce food intake [12,13,14].”
BackgroundNeuropeptide Y Receptor Selective Ligands in the Treatment of Obesity
Kamiji, M. M., & Inui, A. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0003 · Cited by 108
Flannery, B. M., Clark, E., & Pestka, J. J. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs255 · Cited by 105
“Furthermore, humans given exogenous PYY to suppress appetite as an obesity treatment exhibit, at the highest doses, adverse effects that include excessive fullness, abdominal discomfort, nausea, and vomiting (Degen et al., 2005; Gantz et al., 2007).”
BackgroundRecent advances in clinical practice challenges and opportunities in the management of obesity
Acosta, A., Abu Dayyeh, B. K., Port, J. D., & Camilleri, M. (2014) · Gut · doi:10.1136/gutjnl-2013-306235 · Cited by 91
“…after RYGB 92 A large phase II clinical trial of intranasal peptide YY 3 – 36 had to be discontinued early due to severe nausea and vomiting, 93 which is most likely explained by PYY stimulating the area postrema in the brainstem resulting in nausea 50 or delay in gastric emptying induced…”
BackgroundGlucocorticoids, stress and eating: The mediating role of appetite‐regulating hormones
Kuckuck, S., van der Valk, E. S., Scheurink, A. J. W., van der Voorn, B., Iyer, A. M., Visser, J. A., Delhanty, P. J. D., van den Berg, S. A. A., & van Rossum, E. F. C. (2022) · Obesity Reviews · doi:10.1111/obr.13539 · Cited by 105
“128,132,137 Thus, the field of pharmacological PYY treatment is advancing to overcome adverse side effects (including nausea and vomiting) and to provide PYY-analog-based options for therapeutic use.(138,139)”
BackgroundRichards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 92
Kovalainen, M., Mönkäre, J., Mäkilä, E. M., Salonen, J., Lehto, V., Herzig, K., & Järvinen, K. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0611-6 · Cited by 87
“In humans, intranasal delivery of PYY3-36 has been tested in obese adults (33).”
BackgroundPharmacotherapy for childhood obesity: present and future prospects
Sherafat‐Kazemzadeh, R., Yanovski, S. Z., & Yanovski, J. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.144 · Cited by 93
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Roth, J. D., Coffey, T., Jodka, C. M., Maier, H., Athanacio, J. R., Mack, C. M., Weyer, C., & Parkes, D. G. (2007) · Endocrinology · doi:10.1210/en.2007-0898 · Cited by 77
“Finally, a 4 3 factorial design was used to formally describe the interaction between amylin and PYY[3–36].”
BackgroundMethodInfluentialDevelopment of Porous Silicon Nanocarriers for Parenteral Peptide Delivery
Kovalainen, M., Mönkäre, J., Kaasalainen, M. H., Riikonen, J., Lehto, V., Salonen, J., Herzig, K., & Järvinen, K. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300494p · Cited by 74
Present and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 95
Factors affecting circulating levels of peptide YY in humans: a comprehensive review
Cooper, J. A. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000109 · Cited by 86
“The first issue is the severe gastrointestinal side effects that have been reported with moderate doses up to supraphysiological doses of PYY3–36 ((73,74)), which greatly limits its impact as a therapeutic target for obesity.”
BackgroundEffects of Peripherally Administered Neuromedin U on Energy and Glucose Homeostasis
Peier, A. M., Desai, K., Hubert, J. A., Du, X., Yang, L., Qian, Y., Kosinski, J. R., Metzger, J. M., Pocai, A., Nawrocki, A. R., et al. (2011) · Endocrinology · doi:10.1210/en.2010-1463 · Cited by 73
CCK, PYY and PP: The Control of Energy Balance
Simpson, K. A., Parker, J., Plumer, J., & Bloom, S. R. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_9 · Cited by 73
Brain imaging studies of appetite in the context of obesity and the menstrual cycle
Van Vugt, D. A. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp051 · Cited by 69
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Appetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity
Gan, H.-W., Cerbone, M., & Dattani, M. T. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad033 · Cited by 65
“However, development of longer-term PYY-based therapies has been impeded by a lack of efficacy and side effects of nausea and vomiting (210, 211).”
Rodgers, R. J., Holch, P., & Tallett, A. J. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.001 · Cited by 68
Rangwala, S. M., D’Aquino, K., Zhang, Y.-M., Bader, L., Edwards, W., Zheng, S., Eckardt, A., Lacombe, A., Pick, R., Moreno, V., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.017 · Cited by 65
“This inability to separate FI from emesis has undermined the development of PYY-based therapeutics for obesity (Gantz et al., 2007).”
BackgroundObesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64
What is the prognosis for new centrally-acting anti-obesity drugs?
Heal, D. J., Gosden, J., & Smith, S. L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.017 · Cited by 70
“The higher dose was not well tolerated mainly due to nausea and vomiting (Gantz et al., 2007).”
Wu, W., Bates, M. A., Bursian, S. J., Flannery, B. M., Zhou, H.-R., Link, J. E., Zhang, H., & Pestka, J. J. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft033 · Cited by 63
Obesity pharmacotherapy: What is next?
Colon-Gonzalez, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.005 · Cited by 62
“A therapeutic limitation of PYY is that it produces nausea and vomiting in a dose-dependent manner (Degen et al., 2005; Gantz et al., 2007; Steinert et al., 2010).”
BackgroundModulation of neuropeptide Y receptors for the treatment of obesity
Sato, N., Ogino, Y., Mashiko, S., & Ando, M. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903251722 · Cited by 66
“reported a 12-week proofof-concept clinical trial to evaluate the efficacy of intranasal PYY3 – 36 for inducing weight loss in obese patients [78].”
BackgroundGhrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants
Kirchner, H., Tong, J., Tschöp, M. H., & Pfluger, P. T. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00191.2009 · Cited by 57
“In addition, there is concern that a possible suppressive effect of PYY on food intake may merely be the indirect result of nausea, which was previously described as a major and very frequent side effect of PYY administration in a number of human studies (32, 43, 110).”
BackgroundDuca, F. A., & Covașă, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000529 · Cited by 57
“PYY(3–36), its analogues or combination therapy have had only modest results((172,173)).”
BackgroundCentral and Peripheral Molecular Targets for Antiobesity Pharmacotherapy
Valentino, M. A., Lin, J. E., & Waldman, S. A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.57 · Cited by 51
“Unfortunately, >50% of the subjects who received 600 μg of PYY (3-36) withdrew from the study because of nausea and vomiting,26 indicating that further improvements need to be made to the formulation and/or delivery method of PYY.”
BackgroundPharmacotherapy of obesity: emerging drugs and targets
Chakrabarti, R. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802637063 · Cited by 52
“Unfortunately, it did not show any weight loss [40] .”
BackgroundGut Peptides: Targets for Antiobesity Drug Development?
Moran, T. H., & Dailey, M. J. (2009) · Endocrinology · doi:10.1210/en.2009-0003 · Cited by 49
“Both peripheral and central sites of action for PYY(3-36) for inhibiting food intake have been proposed.”
BackgroundInfluentialPeptides and Their Potential Role in the Treatment of Diabetes and Obesity
Greenwood, H. C., Bloom, S. R., & Murphy, K. G. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.355 · Cited by 48
“Intranasal administration resulted in transiently high circulating levels of PYY associated with nausea [96].”
BackgroundRegulation of appetite to treat obesity
Kim, G. W., Lin, J. E., Valentino, M. A., Colón‐González, F., & Waldman, S. A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.3 · Cited by 56
Old Paradoxes and New Opportunities for Appetite Control in Obesity
Montégut, L., López-Otín, C., Magnan, C., & Kroemer, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.005 · Cited by 48
Pharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 67
Do we need anti‐obesity drugs?
Hainer, V., & Hainerová, I. A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2349 · Cited by 51
“In 2008, trials with nasal spray PYY3-36 were stopped as the obtained results did not meet the primary endpoints [83].”
ResultPeptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
“Unfortunately, frequent adverse effects are associated with PYY3− 36 administration (nausea and vomiting) [130], and difficulties in generating analogs of PYY1− 36 that are resistant to DPP-4 degradation, without losing efficacy of β-cell survival and growth [128] makes this ambition challenging.”
New Targets for Drug Treatment of Obesity
Valsamakis, G., Konstantakou, P., & Mastorakos, G. P. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104735 · Cited by 48
Emerging Concepts in the Medical and Surgical Treatment of Obesity
Aylwin, S., & Al-Zaman, Y. (2008) · Frontiers of Hormone Research · doi:10.1159/000115368 · Cited by 41
Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding
Woodward, O. R. M., Gribble, F. M., Reimann, F., & Lewis, J. E. (2022) · The Journal of Physiology · doi:10.1113/jp280581 · Cited by 40
“The nauseating effect of PYY at higher doses has limited its value as an obesity target to date (Gantz et al. 2007; Sloth et al. 2007; le Roux et al. 2008).”
BackgroundGut peptide regulation of food intake - evidence for the modulation of hedonic feeding.
Woodward, O. R. M., Gribble, F. M., Reimann, F. M., & Lewis, J. E. (2021) · Apollo (University of Cambridge) · doi:10.17863/cam.74301 · Cited by 37
Tan, T. M. ‐., Minnion, J., Khoo, B., Ball, L., Malviya, R., Day, E., Fiorentino, F., Brindley, C., Bush, J., & Bloom, S. R. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14358 · Cited by 34
“Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations
Roth, J. D., Trevaskis, J. L., Turek, V. F., & Parkes, D. G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.027 · Cited by 37
“For example, an immediate consequence of dieting is to decrease the meal-induced secretion of shortterm satiogenic signals which are released in proportion to meal size (e.g., amylin, CCK and PYY3–36).”
BackgroundInfluentialJones, E. S., Nunn, N., Chambers, A. P., Østergaard, S., Wulff, B. S., & Luckman, S. M. (2019) · Endocrinology · doi:10.1210/en.2019-00100 · Cited by 33
Nanocarrier for Oral Peptide Delivery Produced by Polyelectrolyte Complexation in Nanoconfinement
He, W. J., Parowatkin, M., Mailänder, V., Flechtner‐Mors, M., Graf, R., Best, A., Koynov, K., Mohr, K., Ziener, U., Landfester, K., et al. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00500 · Cited by 32
Translational studies on PYY as a novel target in obesity
Zac‐Varghese, S., Silva, A. D., & Bloom, S. R. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.001 · Cited by 37
Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 38
Wang, S., Yang, L., Lu, J.-M., & Mu, Y. (2014) · Hormone Research in Paediatrics · doi:10.1159/000362168 · Cited by 38
Ueno, H., Mizuta, M., Shiiya, T., Tsuchimochi, W., Noma, K., Nakashima, N., Fujihara, M., & Nakazato, M. (2014) · Diabetes Care · doi:10.2337/dc13-0690 · Cited by 32
Wu, W., Zhou, H.-R., Bursian, S. J., Link, J. E., & Pestka, J. J. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw191 · Cited by 30
Obesity Pharmacotherapy: Current Perspectives and Future Directions
Misra, M. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076322 · Cited by 36
“More recently, interest has focused on the stimulation of presynaptic NPY2 receptors in the arcuate nucleus as a mechanism to reduce NPY release and, thus, food intake [131].”
BackgroundHenry, K. E., Elfers, C., Burke, R. M., Chepurny, O. G., Holz, G. G., Blevins, J. E., Roth, C. L., & Doyle, R. P. (2015) · Endocrinology · doi:10.1210/en.2014-1825 · Cited by 28
“In addition, rapid increases in PYY3–36 levels can lead to nausea (18) as well as peptide-induced malaise via high dosing in mice (19) and humans (20).”
BackgroundNational survey of pediatric fever management practices among emergency department nurses.
Thomas, V., Riegel, B. J., Andrea, J., Murray, P., Gerhart, A. E., & Gocka, I. (1994) · PubMed · Cited by 32
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Αλεξιάδου, Κ., & Tan, T. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01309-9 · Cited by 27
New advances in models and strategies for developing anti-obesity drugs
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.792804 · Cited by 37
“However, intranasal delivery of PYY (Nastech/Merck) failed to induce weight loss in humans [114].”
BackgroundChandarana, K., & Batterham, R. L. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f3f4b1 · Cited by 32
Role of enteroendocrine hormones in appetite and glycemia
Ricardo-Silgado, M. L., MCRAE, A. N., & Acosta, A. J. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100332 · Cited by 32
Adult-onset PYY overexpression in mice reduces food intake and increases lipogenic capacity
Shi, Y., Hammerle, C. M., Lee, I.-C. J., Turner, N. A., Nguyen, A., Riepler, S. J., Lin, S., Sainsbury, A., Herzog, H., & Zhang, L. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.04.001 · Cited by 26
“…homeostasis is important for the development of PYY-based anti-obesity and anti-diabetes therapies, particularly considering that nausea and vomiting are common side-effects associated with PYY3-36 treatment (Degen et al., 2005, Gantz et al., 2007, Sloth et al., 2007 and le Roux et al., 2008).”
BackgroundMuzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, B. C. E., & Tan, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0119 · Cited by 23
Peripheral mechanisms in the control of appetite and related experimental therapies in obesity
Camilleri, M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.04.011 · Cited by 23
“[33] reported, in a study of 133 patients, that intranasal PYY3–36 administered preprandially at doses of 200 μg t.”
BackgroundPhysiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake
Elliott, J. A., Reynolds, J. V., le Roux, C. W., & Docherty, N. G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1245140 · Cited by 22
“Alternative modes of delivery such as nasal and buccal sprays were attempted in order to overcome the inherent drawback of subcutaneous injection which may limit the patient acceptability of the GLP-1-based agents, but rapid PYY peaks were associated with significant nausea resulting in discontinuation of treatment in…”
BackgroundKushner, R. F. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1339 · Cited by 24
“In a 12-week trial, 133 obese patients received placebo or 200 or 600 μg of PYY3-36 by intranasal spray 20 min before meals in conjuction with a hypocaloric diet and exercise [80] .”
MethodTargeting metabolic and cognitive pathways of the CNS by intranasal insulin administration
Hallschmid, M., Benedict, C., Born, J., & Kern, W. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.319 · Cited by 23
Pharmacotherapy for Obese Adolescents
Greydanus, D. E., Bricker, L. A., & Feucht, C. L. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.10.007 · Cited by 20
Scott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 20
“Early attempts to deliver PYY(3–36) intranasally led to problematic nausea, consequent on rapid absorption and development of supraphy- siological levels of PYY (Gantz et al., 2007; le Roux et al., 2008).”
BackgroundThe Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22
Emerging drugs for obesity therapy
Zanella, M. T., & Filho, F. F. R. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000200019 · Cited by 26
Salivary Peptide Tyrosine–Tyrosine 3–36 Modulates Ingestive Behavior without Inducing Taste Aversion
Hurtado, M. D., Sergeyev, V., Acosta, A. J., Spegele, M., Sala, M. S. L., Waler, N. J., Chiriboga-Hurtado, J., Currlin, S., Herzog, H., Dotson, C. D., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1064-13.2013 · Cited by 21
“Incidentally, neurons in the area postrema (AP) of the brainstem are known to partially mediate TA in response to the PYY3–36 administered peripherally (Halatchev and Cone, 2005) or by intranasal spray (Gantz et al., 2007).”
BackgroundField, B. C. T. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu001 · Cited by 23
Wulff, B. S., Chambers, A. P., Contreras, C. K. O., Kirkeby, K., Rinnov, A. R., Sustarsic, R. K., Østergaard, S., Laabs, J. E., & O'Neil, P. M. (2025) · Obesity · doi:10.1002/oby.24329 · Cited by 19
Rubinić, I., Kurtov, M., & Likić, R. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1243 · Cited by 27
Pedersen, S. L., Holst, B., Vrang, N., & Jensen, K. J. (2009) · Journal of Peptide Science · doi:10.1002/psc.1170 · Cited by 18
Neff, L. M., & Aronne, L. J. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0061-0 · Cited by 22
“However, a recent clinical trial comparing two doses of intranasal PYY with placebo for 12 weeks failed to show a benefit of PYY therapy in obese subjects [ 54 ].”
BackgroundPharmacological Treatment of Obesity
Yoo, S. J. (2008) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2008.23.4.223 · Cited by 18
Kenkre, J. S., Tan, T., & Bloom, S. R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.5 · Cited by 17
Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
Will, S., Hornigold, D. C., Baker, D. J., Coghlan, M. P., Mesquita, M., Trevaskis, J. L., & Naylor, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.010 · Cited by 16
A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation
Walles, M., Berna, M. J., Jian, W., Hauri, S., Hengel, S. M., King, L. M., Tran, J. C., Wei, C., Xu, K., & Zhu, X. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000462 · Cited by 16
Metadata
- Authors
- Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., Wagner, J. A., MacNeil, D. J., Heymsfield, S. B., & Amatruda, J. M.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Gantz, Ira
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-05-01
- Volume
- 92
- Issue
- 5
- Pages
- 1754-1757
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118965081
- Cited by
- 163
- References
- 51
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 12 · 2013: 10 · 2012: 13
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- PYY3-36, intranasal administration, weight loss, obesity, satiety hormones, hypocaloric diet, physical activity, nausea and vomiting, drug safety and tolerability, appetite regulation, gastrointestinal hormones, obesity pharmacotherapy, dose comparison, treatment discontinuation
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Aged, Body Weight, Diet, Reducing, Dose-Response Relationship, Drug, Double-Blind Method, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Peptide Fragments, Weight Loss, Body Mass Index, Treatment Outcome, Peptide YY
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.